This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sbarouni, E. Articles by Kremastinos, D. T. Search for Related Content PubMed PubMed Citation Articles by Sbarouni, E. Articles by Kremastinos, D. T.

CLINICAL STUDIES

The effect of hormone replacement therapy alone and in combination with simvastatin on plasma lipids of hypercholesterolemic postmenopausal women with coronary artery disease

^a 2nd Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece

Manuscript received March 9, 1998; revised manuscript received June 17, 1998, accepted July 6, 1998.

Address for correspondence: Dr. Eftihia Sbarouni, 2nd Department of Cardiology, Onassis Cardiac Surgery Center, 356 Sygrou Avenue, 176 74 Athens, Greece

Objectives. This study sought to compare hormone replacement therapy (HRT), simvastatin and their combination in the management of hypercholesterolemia in postmenopausal women with coronary artery disease (CAD).

Background. Lipid-lowering therapy reduces mortality in hypercholesterolemic women with CAD. In postmenopausal women HRT seems to increase survival, particularly those with ischemic heart disease, and this is partly due to changes in lipid levels.

Methods. We studied 16 postmenopausal women with CAD and fasting total cholesterol <200 mg/dl and low-density lipoprotein (LDL) cholesterol <130 mg/dl. We compared HRT (0.625 mg of conjugated estrogen and 2.5 mg of medroxyprogesterone acetate daily) with simvastatin (20 mg daily) and their combination in a randomized, crossover, placebo-controlled study. Each treatment period was 8 weeks long with a 4-week washout interval between treatments.

Results. Simvastatin, HRT and their combination significantly reduced total and LDL cholesterol by 35%, 13%, and 33% and 45%, 20%, and 46%, respectively, compared to placebo (p < 0.001). However, simvastatin and the combination was superior to HRT (p < 0.001), and none of our patients had total cholesterol <180 mg/dl and LDL cholesterol <100 mg/dl on HRT alone. High-density lipoprotein cholesterol was not significantly affected by any of the active treatments, and triglycerides were lower during simvastatin therapy compared to placebo (p < 0.01). Apolipoprotein B was significantly reduced by simvastatin, alone and combined with HRT, by 39% and 35%, respectively, compared to placebo (p < 0.001). Alone and in combination with simvastatin, HRT significantly increased apolipoprotein A-I by 11% and 12%, respectively, compared to placebo (p < 0.05) and decreased lipoprotein (a) by 23% and 33%, respectively, compared to placebo (p < 0.05), whereas simvastatin had no significant effect on either of these parameters.

Conclusions. In hypercholesterolemic postmenopausal women with CAD, HRT exerts beneficial effects on plasma lipids but the levels currently recommended for secondary prevention are not achieved. Hormone replacement therapy combined with simvastatin is well tolerated and extremely effective, as the two therapies seem to be additive.

Abbreviations and Acronyms   CAD = coronary artery disease   CARE = Cholesterol and Recurrent Events Trial   4 S = Scandinavian Simvastatin Survival Study   HDL = high-density lipoprotein   HMG-CoA = 3-hydroxy-3-methylglutaryl coenzyme A   HRT = hormone replacement therapy   LDL = low-density lipoprotein   Lpa = lipoprotein (a)   NCEP = National Cholesterol Education Program

This article has been cited by other articles:

				The ESHRE Capri Workshop Group Hormones and cardiovascular health in women Hum. Reprod. Update, September 1, 2006; 12(5): 483 - 497. [Abstract] [Full Text] [PDF]

				C J Malkin, P J Pugh, P D Morris, K E Kerry, R D Jones, T H Jones, and K S Channer Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life Heart, August 1, 2004; 90(8): 871 - 876. [Abstract] [Full Text] [PDF]

				C. J. Malkin, P. J. Pugh, R. D. Jones, D. Kapoor, K. S. Channer, and T. H. Jones The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3313 - 3318. [Abstract] [Full Text] [PDF]

				D. M. Herrington, E. Vittinghoff, F. Lin, J. Fong, F. Harris, D. Hunninghake, V. Bittner, H. G. Schrott, R. S. Blumenthal, R. Levy, et al. Statin Therapy, Cardiovascular Events, and Total Mortality in the Heart and Estrogen/Progestin Replacement Study (HERS) Circulation, June 25, 2002; 105(25): 2962 - 2967. [Abstract] [Full Text] [PDF]

				J. C. LaRosa Prevention and Treatment of Coronary Heart Disease: Who Benefits? Circulation, October 2, 2001; 104(14): 1688 - 1692. [Abstract] [Full Text] [PDF]

				F. K. Welty Cardiovascular Disease and Dyslipidemia in Women Arch Intern Med, February 26, 2001; 161(4): 514 - 522. [Abstract] [Full Text] [PDF]

				Z. S. Kyriakides, P. Petinakis, L. Kaklamanis, E. Sbarouni, P. Karayannakos, D. Iliopoulos, I. Dontas, and D. Th. Kremastinos Intramuscular administration of estrogen may promote angiogenesis and perfusion in a rabbit model of chronic limb ischemia Cardiovasc Res, February 16, 2001; 49(3): 626 - 633. [Abstract] [Full Text] [PDF]

				L. Mosca The Role of Hormone Replacement Therapy in the Prevention of Postmenopausal Heart Disease Arch Intern Med, August 14, 2000; 160(15): 2263 - 2272. [Abstract] [Full Text] [PDF]

				A.S Fak, M Erenus, H Tezcan, O Caymaz, P AtagunduZ, S Oktay, and A Oktay Effects of simvastatin only or in combination with continuous combined hormone replacement therapy on serum lipid levels in hypercholesterolaemic post-menopausal women Eur. Heart J., February 1, 2000; 21(3): 190 - 197. [Abstract] [PDF]